JP2022031478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022031478A5 JP2022031478A5 JP2021212103A JP2021212103A JP2022031478A5 JP 2022031478 A5 JP2022031478 A5 JP 2022031478A5 JP 2021212103 A JP2021212103 A JP 2021212103A JP 2021212103 A JP2021212103 A JP 2021212103A JP 2022031478 A5 JP2022031478 A5 JP 2022031478A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- patient
- therapeutic agent
- status
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical group N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 4
- 229950011068 niraparib Drugs 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 2
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- -1 tosylate salt monohydrate Chemical class 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US62/356,461 | 2016-06-29 | ||
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US62/402,427 | 2016-09-30 | ||
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| US62/470,141 | 2017-03-10 | ||
| JP2018568951A JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568951A Division JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022031478A JP2022031478A (ja) | 2022-02-18 |
| JP2022031478A5 true JP2022031478A5 (https=) | 2022-11-04 |
Family
ID=60787744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568951A Active JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
| JP2021212103A Pending JP2022031478A (ja) | 2016-06-29 | 2021-12-27 | 卵巣癌の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568951A Active JP7083760B2 (ja) | 2016-06-29 | 2017-06-29 | 卵巣癌の治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US12383542B2 (https=) |
| EP (2) | EP3478286B1 (https=) |
| JP (2) | JP7083760B2 (https=) |
| KR (2) | KR20230042136A (https=) |
| CN (1) | CN109640992A (https=) |
| AU (1) | AU2017290244B2 (https=) |
| BR (1) | BR112018077492A2 (https=) |
| CA (1) | CA3029671C (https=) |
| DK (1) | DK3478286T3 (https=) |
| ES (1) | ES2969816T3 (https=) |
| FI (1) | FI3478286T3 (https=) |
| HR (1) | HRP20240136T1 (https=) |
| HU (1) | HUE064978T2 (https=) |
| IL (1) | IL263925B2 (https=) |
| LT (1) | LT3478286T (https=) |
| MX (1) | MX394062B (https=) |
| NZ (1) | NZ749413A (https=) |
| PL (1) | PL3478286T3 (https=) |
| PT (1) | PT3478286T (https=) |
| RS (1) | RS65180B1 (https=) |
| SG (1) | SG11201811564QA (https=) |
| SI (1) | SI3478286T1 (https=) |
| SM (1) | SMT202400105T1 (https=) |
| WO (1) | WO2018005818A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| CA3041684C (en) | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| MX2019008208A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| BR112019020211A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro, Inc. | composições de niraparib |
| KR102582624B1 (ko) | 2017-04-24 | 2023-09-22 | 테사로, 인코포레이티드 | 니라파립의 제조 방법 |
| TWI879716B (zh) * | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| AU2019215450A1 (en) * | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| WO2020072797A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Niraparib salts |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| US11640859B2 (en) | 2018-10-17 | 2023-05-02 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| US10957433B2 (en) | 2018-12-03 | 2021-03-23 | Tempus Labs, Inc. | Clinical concept identification, extraction, and prediction system and related methods |
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| US11705226B2 (en) | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| TW202116316A (zh) * | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| US11295841B2 (en) * | 2019-08-22 | 2022-04-05 | Tempus Labs, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| JP2023508996A (ja) * | 2019-12-31 | 2023-03-06 | キネート バイオファーマ インク． | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 |
| EP4090380A1 (en) * | 2020-01-13 | 2022-11-23 | Gradalis, Inc. | Methods for treating cancers using gm-csf encoding polynucleotide and additional agents |
| UY39201A (es) * | 2020-05-08 | 2021-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| KR102858757B1 (ko) | 2022-01-25 | 2025-09-10 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
| CN121866063A (zh) * | 2023-09-19 | 2026-04-14 | 上海瑛派药业有限公司 | Parp抑制剂在卵巢癌维持治疗中的应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007733B1 (en) | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| CA2702429A1 (en) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
| KR20100102607A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| US8500933B2 (en) | 2007-12-14 | 2013-08-06 | Guardian Industries Corp. | Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same |
| CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| ES2572652T3 (es) | 2009-08-26 | 2016-06-01 | Cephalon, Inc. | Nuevas formas de un compuesto multicíclico |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| DK3327148T3 (da) | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| ES2658867T3 (es) | 2012-06-07 | 2018-03-12 | Institut Curie | Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| CA2893280A1 (en) | 2012-11-28 | 2014-06-05 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| EP3094752A4 (en) | 2014-01-16 | 2017-08-16 | Clovis Oncology, Inc. | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
| EA201691376A1 (ru) | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
| CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| US10238630B2 (en) * | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
| CA2959072C (en) | 2014-08-25 | 2025-12-09 | Creatv Microtech, Inc. | Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| HK1251474A1 (zh) | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
| PL3954690T3 (pl) | 2015-07-02 | 2023-08-14 | Acerta Pharma B.V. | Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| CA3014252A1 (en) | 2016-02-12 | 2017-08-17 | Nantomics, Llc | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies |
| US11154538B2 (en) * | 2016-02-29 | 2021-10-26 | Synta Pharmaceuticals Corporation | Combination therapy for treatment of ovarian cancer |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432055A (zh) | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| BR112019020211A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro, Inc. | composições de niraparib |
| KR102582624B1 (ko) | 2017-04-24 | 2023-09-22 | 테사로, 인코포레이티드 | 니라파립의 제조 방법 |
| EP3615572A1 (en) | 2017-04-27 | 2020-03-04 | Tesaro Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| WO2019005762A1 (en) | 2017-06-26 | 2019-01-03 | Abbvie Inc. | TREATMENT OF NON-SMALL CELL LUNG CANCER |
| KR20250016494A (ko) | 2017-09-26 | 2025-02-03 | 테사로, 인코포레이티드 | 니라파립 제제 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| SG11202006147SA (en) | 2017-12-27 | 2020-07-29 | Tesaro Inc | Methods of treating cancer |
| TW202116316A (zh) | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| KR102336493B1 (ko) | 2019-11-22 | 2021-12-07 | 주식회사 메디풀 | 항균탈취 조성물 및 이의 제조방법 |
-
2017
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Ceased
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en not_active Ceased
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt not_active Application Discontinuation
- 2017-06-29 MX MX2018016193A patent/MX394062B/es unknown
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 SM SM20240105T patent/SMT202400105T1/it unknown
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active Active
-
2018
- 2018-05-22 US US15/986,536 patent/US12383542B2/en active Active
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/ja active Pending
-
2022
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US12527780B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031478A5 (https=) | ||
| JP2019524690A5 (https=) | ||
| FI3478286T3 (fi) | Menetelmiä munasarjasyövän hoitamiseksi | |
| JP2022022264A5 (https=) | ||
| JPWO2023190748A5 (https=) | ||
| JP2021526132A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| IL257147A (en) | Combined treatment with liposomal irinotecan and parp inhibitor for cancer treatment | |
| JP2014512356A5 (https=) | ||
| JP2014509659A5 (https=) | ||
| JPWO2020053655A5 (https=) | ||
| JP2014518275A5 (https=) | ||
| JP2015523397A5 (https=) | ||
| JP2014530874A5 (https=) | ||
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2015512398A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2017507151A5 (https=) | ||
| JP2009539970A5 (https=) | ||
| JP2015507020A5 (https=) | ||
| JP2017503846A5 (https=) |